Tree Topp

Study Name Tree Topp ClinicalTrials.gov Identifier (if applicable) NCT03093870 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Study Center Institution Name UT MD Anderson Cancer Center Institution Address University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 426, FC10.2051 City Houston State TX Zip Code 77030 Phone 1-877-250-3770 Website mdanderson.org Study Contacts Principal Investigator Dr. Milind Javle P.I. Phone (713) 794-1623 P.I. Email mjavle@mdanderson.org Study Coordinator Kimberly Ross Study Coordinator Phone 713-794-1623 Study Coordinator Email kdross@mdanderson.org List additional Study Coordinators (include phone number and email) Charlotte, North Carolina – Levine Cancer Institute, Carolinas Healthcare System 1021 Morehead Medical Dr.  Charlotte, NC  28204; (980) 442-2000 Contact: Study Coordinator – Melani Terry, (980)-442-2157, Melani.Terry@atriumhealth.org Dallas, Texas – Texas Oncology, P.A., Texas Oncology Sammons Cancer Center 3410 Worth Street, Suite 730 , Dallas, TX 75246; www.texasoncology.com. Detroit, Michigan – Karmanos Cancer Institute/Wayne State University, Karmanos Cancer Center...

GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients

Study Name GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients ClinicalTrials.gov Identifier (if applicable) NCT03316222 Clinical Trial Category (check all that apply) Beyond First Line Therapy Chemotherapy Other Novel Therapy Study Center Institution Name Memorial Sloan Kettering Institution Address 300 E 53rd St City New York State New York Zip Code 10065 Study Contacts Principal Investigator Pr James Harding P.I. Phone (646) 888-4314 P.I. Email hardinj1@mskcc.org List additional Principal Investigators (include phone number and email) Pr Ghassan Abou-Alfa, (646) 888-4184, abou-alg@mskcc.org Study Coordinator Amanda Simms Study Coordinator Phone (646) 888-4314 Study Coordinator Email simmsa@mskcc.org List additional Study Coordinators (include phone number and email) Brittanie Millans, millangb@mskcc.org OVERVIEW – in layman’s terms (150 words max) This is a multicenter, open-label, uncontrolled, repeat-dose phase 1/2a study designed to evaluate the safety profile and to determine...

The 2019 Annual Conference T-Shirt Design Contest

CCF is excited to announce our Annual Conference t-shirt logo contest. The logos will be printed on a white sport t-shirt with green 3/4 sleeves. Contest Rules Use this entry form to submit your logo design Limit design to a maximum of 2 colors Limit design to no larger than 10 inches square 5 designs will be posted on our Facebook page for voting. The winning design will be the logo with the most “likes” Submission deadline is Sunday, September 30th Questions? Email jordan.giles@cholangiocarcinoma.org   Name* First Last What is your relationship with cholangiocarcinoma?Patient (personally diagnosed)CaregiverFriend or Relative of PatientOtherAddress Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFaroe IslandsFijiFinlandFranceFrench PolynesiaGabonGambiaGeorgiaGermanyGhanaGreeceGreenlandGrenadaGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiNorth KoreaSouth KoreaKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalPuerto...

Thoughts and Memories of Marion Schwartz

Marion and I worked together daily for over 10 years building the foundation and we’ve talked often since her retirement. She worked with many of you over the years to make sure the patient voice was considered in all endeavors and she admired the way you treated “her” patients. She took great pride in her work and considered you friends and colleagues. Today, at CCF we will be thinking of Marion, all she accomplished and all those she personally shepherded through life with compassion and great tenderness. She had a wonderful gift that she shared with all of us. She was and will continue to be an enormous blessing to our community. Love to all, Stacie C. Lindsey President & Founder Cholangiocarcinoma Foundation We will all treasure great memories of Marion and her passion for improving care for patients with cholangiocarcinoma. Deepest condolences to her family. Dr. Lewis Roberts...

A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma

Study Name A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable) NCT03086993 Clinical Trial Category (check all that apply) Chemotherapy First Line Therapy Targeted Therapy Study Center Institution Name Duke University Medical Center Institution Address 30 Duke Medicine Circle City Durham State North Carolina Zip Code 27710 Study Contacts Principal Investigator Sabino Zani P.I. Phone (919) 684-6553 P.I. Email sabino.zani@duke.edu Study Coordinator Kimberly Turnage Study Coordinator Phone (919) 681-5559 Study Coordinator Email kimberly.turnage@duke.edu OVERVIEW – in layman’s terms (150 words max) Patients with intrahepatic cholangiocarcinoma who enroll in this study will receive either Melphalan with the investigational Hepatic Delivery System (called Melphalan/HDS) or Cisplatin and Gemcitabine alone, which is standard of care.  Patients who enroll will receive gem/cis followed by melphalan, compared to gem/cis. Enrollment 5...

A Study of TAS-120 in Patients With Advanced Solid Tumors

Study Name A Study of TAS-120 in Patients With Advanced Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT02052778 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name Massachusetts General Hospital Institution Address 55 Fruit Street City Boston State Massachusetts Zip Code 02114 List additional Institutions (include address, phone number, and website) 1. Sarah Cannon Research Institute – 93 Harley Street, London, W1G 6AD, UK 2. Institute Goustave-Roussy – 39 Rue Camille Desmoulins, Villejuif Cedex, Paris, 94805, France 3. Royal Melbourne Hospital – 305 Grattan Street, Melbourne, Victoria, 3000 Australia 4. Greenville Health System ITOR – 900 W. Faris Rd., CTC 3rd floor, Greenville, SC 29605, USA 5. Centre Léon Bérard Bât – 28 rue Laennec, Lyon 69008, France 6. INSTITUT BERGONIE – 229 COURS DE L‘ARGONNE, BORDEAUX 33076 France 7. Pitié-Salpêtrière Hospital – 47-83 Bd de l’Hopital, Paris 75013, France 8. University Hospital Ramón y Cajal – Oficina de Ensayos Clínicos...

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Study Name A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer ClinicalTrials.gov Identifier (if applicable) NCT03482102 Clinical Trial Category (check all that apply) Beyond First Line Therapy Immunotherapy Radiation Therapy Study Center Institution Name Massachusetts General Hospital Institution Address 55 Fruit Street City Boston State Massachusetts Zip Code 02114 List additional Institutions (include address, phone number, and website) This study is also being conducted at Dana Farber Cancer Institute (DFCI)/Brigham & Women’s Hospital (BWH). Study Contacts Principal Investigator Theodore S. Hong, MD P.I. Phone (617) 726-6050 P.I. Email TSHONG1@mgh.harvard.edu List additional Principal Investigators (include phone number and email) This study is also being conducted at Dana Farber Cancer Institute/Brigham & Women’s Hospital. Site Principal Investigator: Jeffrey A. Meyerhardt, MD, MPH Phone: 617-632-6855 Email: Jeffrey_Meyerhardt@dfci.harvard.edu Study Coordinator Leilana Ly Study Coordinator Phone (617) 726-8114 Study Coordinator Email LLY2@mgh.harvard.edu List additional Study...

A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Study Name A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT03329950 Clinical Trial Category (check all that apply) Beyond First Line Therapy Immunotherapy Study Center Institution Name HonorHealth Research Insititute Institution Address 10510 N. 92nd Street City Scottsdale State Arizona Zip Code 85258 Phone (480) 323-1350 List additional Institutions (include address, phone number, and website) Icahn School of Medicine at Mount Sinai (New York, NY 10029. 212-824-8449). Memorial Sloan Kettering Cancer Center (New York, NY 10065. 646-888-4384) Providence Portland Medical Center (Portland, OR 97213. 503-215-7192) Abramson Cancer Center at the University of Pennsylvania (Philadelphia, PA 19104. 215-614-7677) Study Contacts Principal Investigator Michael Gordon, MD P.I. Phone (480) 323-1350 P.I. Email michael.gordon@honorhealth.com List additional Principal Investigators (include phone number and email) Nina Bhardwaj, MD at Mount Sinai (contact Melissa Diamond at 212-824-8449 or melissa.diamond@mssm.edu) Danny Khalil,...

Avery’s Ice Cream for a Cure

Avery has a huge love for ice cream and all things chocolate. She also wants to help find a cure for cancer, specifically cholangiocarcinoma, in memory of her grandmother. So this sweet 9 year old decided to use her love of ice cream to raise money and awareness for the The Cholangiocarcinoma Foundation. Avery‘s Ice Cream for a Cure fundraiser in February generated over...

Publix Georgia Half Marathon

I successfully completed the Publix Georgia Half Marathon this morning. With the support of some great friends and family, we were able to raise $5,200 (counting $200 I understand was sent directly to the CCF) for the Cholangiocarcinoma Foundation. I am humbled and honored by all the support I’ve received, and I hope these funds help further the great work of the CCF! Thanks for your help and guidance getting the Crowdrise site set up! Fred...

Phase I study of ZW25 (bispecific antibody) in patients with advanced HER2-expressing cancers

Study Name Phase I study of ZW25 (bispecific antibody) in patients with advanced HER2-expressing cancers ClinicalTrials.gov Identifier (if applicable) NCT02892123 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name MD Anderson Institution Address Investigational Cancer Therapeutics City Houston State Texas Zip Code 77030 List additional Institutions (include address, phone number, and website) Sarah Cannon. Nashville, TN START, SanAntonio, TX University of Colorado, Denver, CO USC/Norris cancer center, Los Angeles, CA North West Medical Specialist, Tacoma, WA Study Contacts Principal Investigator Dr. Meric Bernstam P.I. Phone (713) 794-1226 P.I. Email fmeric@mdanderson.org List additional Principal Investigators (include phone number and email) Dr. Erika Hamilton Dr. Murali Beeram Dr. Jose Mayordomo Dr. Diana Hanna Dr. Chaves Study Coordinator Kavitha Balaji Study Coordinator Phone (713) 745-7559 Study Coordinator Email kbalaji@mdanderson.org List additional Study Coordinators (include phone number and email) START: isabel.jimenez@startsa.com; 210-593-5261 North West Medical Specialist: idhaene@nwsonline.com; 253-428-8753 OVERVIEW...

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Study Name Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations ClinicalTrials.gov Identifier (if applicable) NCT01948297 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name The University of Texas MD Anderson Cancer Center Institution Address 1515 Holcombe Blvd City Houston State Texas Zip Code 77030 Phone (713) 745-0746 Website http://www.mdanderson.org List additional Institutions (include address, phone number, and website) Dana-Farber Cancer Institute – Boston, Massachusetts, United States Massachusetts General Hospital – Boston, Massachusetts, United States Memorial Sloan-Kettering Hospital – New York, New York, United States Seoul National University Hospital – Seoul, Republic of Korea National Cancer Center Singapore – Singapore, Singapore Vall d’Hebron University Hospital – Barcelona, Spain Taipei Medical University Hospital – Taipei, Taiwan Study Contacts Principal Investigator Dr. Funda Meric-Bernstam P.I. Phone (713) 794-1226 P.I. Email fmeric@mdanderson.org Study Coordinator Holly Oakley Study...

A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors With FGF/FGFR-Related Abnormalities

Study Name A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors With FGF/FGFR-Related Abnormalities ClinicalTrials.gov Identifier (if applicable) NCT02052778 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name The University of Texas MD Anderson Cancer Center Institution Address 1515 Holcombe Blvd City Houston State Texas Zip Code 77030 Website https://www.mdanderson.org/ List additional Institutions (include address, phone number, and website) USA: Massachusetts General Hospital USA: Greenville Health System ITOR Australia: Royal Melbourne Hospital France: Institut Bergonie France: Centre Léon Bérard Bât France: Pitié-Salpêtrière Hospital France: Institute Goustave-Roussy Spain: Vall D’Hebron University Hospital Spain: University Hospital Ramón y Cajal Spain: Centro Integral Oncológico Clara Campal – Hospital Universitario Madrid Sanchinarro UK: Sarah Cannon Research Institute Study Contacts Principal Investigator Dr. Funda Meric-Bernstam P.I. Phone (713) 794-1226 P.I. Email fmeric@mdanderson.org Study Coordinator Holly Oakley Study Coordinator...
Translate »
Coming Soon.

Pin It on Pinterest